MaxCyte (NASDAQ:MXCT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of MaxCyte (NASDAQ:MXCT) from a sell rating to a hold rating in a report issued on Tuesday morning.

A number of other research analysts have also issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of MaxCyte in a research note on Monday, December 29th. Craig Hallum cut their target price on shares of MaxCyte from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, March 25th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, MaxCyte presently has a consensus rating of “Hold” and a consensus target price of $5.50.

MaxCyte Stock Performance

MXCT stock opened at $0.75 on Tuesday. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $2.96. The company’s 50 day moving average price is $0.80 and its 200 day moving average price is $1.29. The firm has a market capitalization of $80.10 million, a price-to-earnings ratio of -1.74 and a beta of 1.23.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $6.76 million for the quarter, compared to analyst estimates of $9.16 million. MaxCyte had a negative net margin of 135.14% and a negative return on equity of 22.15%. Equities analysts forecast that MaxCyte will post -0.42 EPS for the current fiscal year.

Institutional Investors Weigh In On MaxCyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. bought a new stake in shares of MaxCyte in the 2nd quarter worth about $26,000. State of Wyoming acquired a new stake in shares of MaxCyte in the 2nd quarter worth approximately $38,000. Kwmg LLC boosted its stake in MaxCyte by 75.8% during the third quarter. Kwmg LLC now owns 25,833 shares of the company’s stock valued at $41,000 after buying an additional 11,135 shares in the last quarter. Jain Global LLC bought a new stake in shares of MaxCyte during the 4th quarter worth $45,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of MaxCyte by 39.5% in the third quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock worth $57,000 after buying an additional 10,263 shares during the period. 68.81% of the stock is currently owned by institutional investors and hedge funds.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical?stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical?scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.